Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine.
Identifieur interne : 000749 ( Ncbi/Merge ); précédent : 000748; suivant : 000750Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine.
Auteurs : Min-Sheng Zhu [République populaire de Chine] ; Ying Pan ; Hua-Qun Chen ; Yue Shen ; Xiao-Chun Wang ; Yong-Jun Sun ; Kai-Hua TaoSource :
- Immunology letters [ 0165-2478 ] ; 2004.
Descripteurs français
- KwdFr :
- Animaux, Anticorps (immunologie), Femelle, Lapins, Lymphocytes T cytotoxiques (immunologie), Nucléoprotéines (immunologie), Protéines virales (immunologie), Souris, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (immunologie), Vaccins à ADN (immunologie), Virus du SRAS (immunologie).
- MESH :
English descriptors
- KwdEn :
- Animals, Antibodies (immunology), Female, Mice, Nucleoproteins (immunology), Rabbits, SARS Virus (immunology), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), T-Lymphocytes, Cytotoxic (immunology), Vaccines, DNA (immunology), Viral Proteins (immunology).
- MESH :
- chemical , immunology : Antibodies, Nucleoproteins, Vaccines, DNA, Viral Proteins.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, T-Lymphocytes, Cytotoxic.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Female, Mice, Rabbits.
Abstract
Induction of effective cytotoxic T lymphocyte (CTL) and/or a specific antibody against conserved viral proteins may be essential to the development of a safe and effective severe acute respiratory syndrome coronavirus (SARS-Cov) vaccine. DNA vaccination represents a new strategy for induction of humoral and cellular immune response. To determine the ability of SARS-Cov nucleoprotein (N protein) to induce antiviral immunity, in this report, we established a stable C2C12 line expressing SARS-Cov N protein, which was used as a target for specific CTL assay. We also expressed recombinant N proteins in Escherichia coli and prepared N protein-specific polyclonal antibodies. C3H/He mice were immunized with N protein-expressible pcDN-fn vector by intramuscular injections. We found that the DNA vaccination induced both N protein-specific antibody and specific CTL activity to the target. When C3H/He mice were immunized by three separate injections, high antibody titre (1:3200-1:6400, average titre is 1:4580) and high CTL activity (67.4+/-8.4% (E:T = 25:1), 69.6+/-6.7% (E:T = 50:1) and 71.8+/-6.2% (E:T = 100:1)) were observed. In the case of two vaccine injections, CTL activity was also high (56.6+/-12.7% (E:T = 25:1), 57.4+/-11.7% (E:T = 50:1) and 63.0+/-6.3% (E:T = 100:1)) However, antibody titres were much lower (1:200-1:3200, average titre is 1:980). Our results suggest that SARS-Cov nucleocapsid gene might be a candidate gene for SARS DNA vaccination.
DOI: 10.1016/j.imlet.2004.01.001
PubMed: 15081618
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002E52
- to stream PubMed, to step Curation: 002E52
- to stream PubMed, to step Checkpoint: 002C38
Links to Exploration step
pubmed:15081618Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine.</title><author><name sortKey="Zhu, Min Sheng" sort="Zhu, Min Sheng" uniqKey="Zhu M" first="Min-Sheng" last="Zhu">Min-Sheng Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Huadong Research Institute For Medical Biotechnics, 293 Zhong Shan East Road, Nanjing 210002, PR China. mszhu00@yahoo.com</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Huadong Research Institute For Medical Biotechnics, 293 Zhong Shan East Road, Nanjing 210002</wicri:regionArea><wicri:noRegion>Nanjing 210002</wicri:noRegion></affiliation></author><author><name sortKey="Pan, Ying" sort="Pan, Ying" uniqKey="Pan Y" first="Ying" last="Pan">Ying Pan</name></author><author><name sortKey="Chen, Hua Qun" sort="Chen, Hua Qun" uniqKey="Chen H" first="Hua-Qun" last="Chen">Hua-Qun Chen</name></author><author><name sortKey="Shen, Yue" sort="Shen, Yue" uniqKey="Shen Y" first="Yue" last="Shen">Yue Shen</name></author><author><name sortKey="Wang, Xiao Chun" sort="Wang, Xiao Chun" uniqKey="Wang X" first="Xiao-Chun" last="Wang">Xiao-Chun Wang</name></author><author><name sortKey="Sun, Yong Jun" sort="Sun, Yong Jun" uniqKey="Sun Y" first="Yong-Jun" last="Sun">Yong-Jun Sun</name></author><author><name sortKey="Tao, Kai Hua" sort="Tao, Kai Hua" uniqKey="Tao K" first="Kai-Hua" last="Tao">Kai-Hua Tao</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2004">2004</date><idno type="RBID">pubmed:15081618</idno><idno type="pmid">15081618</idno><idno type="doi">10.1016/j.imlet.2004.01.001</idno><idno type="wicri:Area/PubMed/Corpus">002E52</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002E52</idno><idno type="wicri:Area/PubMed/Curation">002E52</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002E52</idno><idno type="wicri:Area/PubMed/Checkpoint">002C38</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C38</idno><idno type="wicri:Area/Ncbi/Merge">000749</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine.</title><author><name sortKey="Zhu, Min Sheng" sort="Zhu, Min Sheng" uniqKey="Zhu M" first="Min-Sheng" last="Zhu">Min-Sheng Zhu</name><affiliation wicri:level="1"><nlm:affiliation>Huadong Research Institute For Medical Biotechnics, 293 Zhong Shan East Road, Nanjing 210002, PR China. mszhu00@yahoo.com</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Huadong Research Institute For Medical Biotechnics, 293 Zhong Shan East Road, Nanjing 210002</wicri:regionArea><wicri:noRegion>Nanjing 210002</wicri:noRegion></affiliation></author><author><name sortKey="Pan, Ying" sort="Pan, Ying" uniqKey="Pan Y" first="Ying" last="Pan">Ying Pan</name></author><author><name sortKey="Chen, Hua Qun" sort="Chen, Hua Qun" uniqKey="Chen H" first="Hua-Qun" last="Chen">Hua-Qun Chen</name></author><author><name sortKey="Shen, Yue" sort="Shen, Yue" uniqKey="Shen Y" first="Yue" last="Shen">Yue Shen</name></author><author><name sortKey="Wang, Xiao Chun" sort="Wang, Xiao Chun" uniqKey="Wang X" first="Xiao-Chun" last="Wang">Xiao-Chun Wang</name></author><author><name sortKey="Sun, Yong Jun" sort="Sun, Yong Jun" uniqKey="Sun Y" first="Yong-Jun" last="Sun">Yong-Jun Sun</name></author><author><name sortKey="Tao, Kai Hua" sort="Tao, Kai Hua" uniqKey="Tao K" first="Kai-Hua" last="Tao">Kai-Hua Tao</name></author></analytic><series><title level="j">Immunology letters</title><idno type="ISSN">0165-2478</idno><imprint><date when="2004" type="published">2004</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antibodies (immunology)</term><term>Female</term><term>Mice</term><term>Nucleoproteins (immunology)</term><term>Rabbits</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term><term>T-Lymphocytes, Cytotoxic (immunology)</term><term>Vaccines, DNA (immunology)</term><term>Viral Proteins (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Anticorps (immunologie)</term><term>Femelle</term><term>Lapins</term><term>Lymphocytes T cytotoxiques (immunologie)</term><term>Nucléoprotéines (immunologie)</term><term>Protéines virales (immunologie)</term><term>Souris</term><term>Syndrome respiratoire aigu sévère ()</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Vaccins à ADN (immunologie)</term><term>Virus du SRAS (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antibodies</term><term>Nucleoproteins</term><term>Vaccines, DNA</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Anticorps</term><term>Lymphocytes T cytotoxiques</term><term>Nucléoprotéines</term><term>Protéines virales</term><term>Syndrome respiratoire aigu sévère</term><term>Vaccins à ADN</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Female</term><term>Mice</term><term>Rabbits</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Femelle</term><term>Lapins</term><term>Souris</term><term>Syndrome respiratoire aigu sévère</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Induction of effective cytotoxic T lymphocyte (CTL) and/or a specific antibody against conserved viral proteins may be essential to the development of a safe and effective severe acute respiratory syndrome coronavirus (SARS-Cov) vaccine. DNA vaccination represents a new strategy for induction of humoral and cellular immune response. To determine the ability of SARS-Cov nucleoprotein (N protein) to induce antiviral immunity, in this report, we established a stable C2C12 line expressing SARS-Cov N protein, which was used as a target for specific CTL assay. We also expressed recombinant N proteins in Escherichia coli and prepared N protein-specific polyclonal antibodies. C3H/He mice were immunized with N protein-expressible pcDN-fn vector by intramuscular injections. We found that the DNA vaccination induced both N protein-specific antibody and specific CTL activity to the target. When C3H/He mice were immunized by three separate injections, high antibody titre (1:3200-1:6400, average titre is 1:4580) and high CTL activity (67.4+/-8.4% (E:T = 25:1), 69.6+/-6.7% (E:T = 50:1) and 71.8+/-6.2% (E:T = 100:1)) were observed. In the case of two vaccine injections, CTL activity was also high (56.6+/-12.7% (E:T = 25:1), 57.4+/-11.7% (E:T = 50:1) and 63.0+/-6.3% (E:T = 100:1)) However, antibody titres were much lower (1:200-1:3200, average titre is 1:980). Our results suggest that SARS-Cov nucleocapsid gene might be a candidate gene for SARS DNA vaccination.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15081618</PMID><DateCompleted><Year>2004</Year><Month>11</Month><Day>19</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0165-2478</ISSN><JournalIssue CitedMedium="Print"><Volume>92</Volume><Issue>3</Issue><PubDate><Year>2004</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Immunology letters</Title><ISOAbbreviation>Immunol. Lett.</ISOAbbreviation></Journal><ArticleTitle>Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine.</ArticleTitle><Pagination><MedlinePgn>237-43</MedlinePgn></Pagination><Abstract><AbstractText>Induction of effective cytotoxic T lymphocyte (CTL) and/or a specific antibody against conserved viral proteins may be essential to the development of a safe and effective severe acute respiratory syndrome coronavirus (SARS-Cov) vaccine. DNA vaccination represents a new strategy for induction of humoral and cellular immune response. To determine the ability of SARS-Cov nucleoprotein (N protein) to induce antiviral immunity, in this report, we established a stable C2C12 line expressing SARS-Cov N protein, which was used as a target for specific CTL assay. We also expressed recombinant N proteins in Escherichia coli and prepared N protein-specific polyclonal antibodies. C3H/He mice were immunized with N protein-expressible pcDN-fn vector by intramuscular injections. We found that the DNA vaccination induced both N protein-specific antibody and specific CTL activity to the target. When C3H/He mice were immunized by three separate injections, high antibody titre (1:3200-1:6400, average titre is 1:4580) and high CTL activity (67.4+/-8.4% (E:T = 25:1), 69.6+/-6.7% (E:T = 50:1) and 71.8+/-6.2% (E:T = 100:1)) were observed. In the case of two vaccine injections, CTL activity was also high (56.6+/-12.7% (E:T = 25:1), 57.4+/-11.7% (E:T = 50:1) and 63.0+/-6.3% (E:T = 100:1)) However, antibody titres were much lower (1:200-1:3200, average titre is 1:980). Our results suggest that SARS-Cov nucleocapsid gene might be a candidate gene for SARS DNA vaccination.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhu</LastName><ForeName>Min-Sheng</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Huadong Research Institute For Medical Biotechnics, 293 Zhong Shan East Road, Nanjing 210002, PR China. mszhu00@yahoo.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Ying</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hua-Qun</ForeName><Initials>HQ</Initials></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>Yue</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Xiao-Chun</ForeName><Initials>XC</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Yong-Jun</ForeName><Initials>YJ</Initials></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Kai-Hua</ForeName><Initials>KH</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Immunol Lett</MedlineTA><NlmUniqueID>7910006</NlmUniqueID><ISSNLinking>0165-2478</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009698">Nucleoproteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009698" MajorTopicYN="N">Nucleoproteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011817" MajorTopicYN="N">Rabbits</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2003</Year><Month>11</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2004</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2004</Year><Month>01</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>12</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>4</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15081618</ArticleId><ArticleId IdType="doi">10.1016/j.imlet.2004.01.001</ArticleId><ArticleId IdType="pii">S0165247804000045</ArticleId><ArticleId IdType="pmc">PMC7119895</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Di Yi Jun Yi Da Xue Xue Bao. 2003 Jul;23(7):637-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12865207</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 1996 Dec;46(1-2):111-24</Citation><ArticleIdList><ArticleId IdType="pubmed">9029784</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Clin Chem. 2003 Dec;49(12):1989-96</Citation><ArticleIdList><ArticleId IdType="pubmed">14633869</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Jan;72(1):191-200</Citation><ArticleIdList><ArticleId IdType="pubmed">9420215</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Anal Biochem. 1980 Nov 15;109(1):76-86</Citation><ArticleIdList><ArticleId IdType="pubmed">6258458</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1779-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12781537</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Beijing Da Xue Xue Bao Yi Xue Ban. 2003 May 31;35 Suppl:23-5</Citation><ArticleIdList><ArticleId IdType="pubmed">12914210</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Immunol. 2003 Nov 15;171(10):5415-22</Citation><ArticleIdList><ArticleId IdType="pubmed">14607945</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 1999 Dec 1;65(1):75-86</Citation><ArticleIdList><ArticleId IdType="pubmed">10564754</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1998 Jun 20;246(1):134-44</Citation><ArticleIdList><ArticleId IdType="pubmed">9657001</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2001 Mar;75(6):2660-4</Citation><ArticleIdList><ArticleId IdType="pubmed">11222689</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Dec 6;362(9399):1895-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14667748</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Vaccine. 1999 Nov 12;18(7-8):681-91</Citation><ArticleIdList><ArticleId IdType="pubmed">10547428</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Annu Rev Immunol. 1997;15:617-48</Citation><ArticleIdList><ArticleId IdType="pubmed">9143702</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2003 Jul 31;349(5):508-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12890855</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 1998 Jul;72(7):5648-53</Citation><ArticleIdList><ArticleId IdType="pubmed">9621023</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2003 Oct;25(5):542-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14650154</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>République populaire de Chine</li></country></list><tree><noCountry><name sortKey="Chen, Hua Qun" sort="Chen, Hua Qun" uniqKey="Chen H" first="Hua-Qun" last="Chen">Hua-Qun Chen</name><name sortKey="Pan, Ying" sort="Pan, Ying" uniqKey="Pan Y" first="Ying" last="Pan">Ying Pan</name><name sortKey="Shen, Yue" sort="Shen, Yue" uniqKey="Shen Y" first="Yue" last="Shen">Yue Shen</name><name sortKey="Sun, Yong Jun" sort="Sun, Yong Jun" uniqKey="Sun Y" first="Yong-Jun" last="Sun">Yong-Jun Sun</name><name sortKey="Tao, Kai Hua" sort="Tao, Kai Hua" uniqKey="Tao K" first="Kai-Hua" last="Tao">Kai-Hua Tao</name><name sortKey="Wang, Xiao Chun" sort="Wang, Xiao Chun" uniqKey="Wang X" first="Xiao-Chun" last="Wang">Xiao-Chun Wang</name></noCountry><country name="République populaire de Chine"><noRegion><name sortKey="Zhu, Min Sheng" sort="Zhu, Min Sheng" uniqKey="Zhu M" first="Min-Sheng" last="Zhu">Min-Sheng Zhu</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000749 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 000749 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Ncbi
|étape= Merge
|type= RBID
|clé= pubmed:15081618
|texte= Induction of SARS-nucleoprotein-specific immune response by use of DNA vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:15081618" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |